Anti-Müllerian hormone: correlation with testosterone and oligo- or amenorrhoea in female adolescence in a population-based cohort study. by Pinola, P et al.
ORIGINAL ARTICLE Reproductive endocrinology
Anti-Mu¨llerian hormone: correlation
with testosterone and oligo- or
amenorrhoea in female adolescence
in a population-based cohort study
P.Pinola1,L.C.Morin-Papunen1,*,A.Bloigu2,K.Puukka3,A.Ruokonen3,
M.-R. Ja¨rvelin2,4,5,6,7, S. Franks8, J.S. Tapanainen1,9, and H. Lashen10
1Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu and Medical Research Center Oulu, Oulu, Finland
2Department of Children and Young People and Families, National Institute for Health andWelfare, Aapistie 1, Box 310, FI-90101Oulu, Finland
3NordLabOulu,OuluUniversityHospital andDepartment ofClinical Chemistry,UniversityofOulu,Oulu, Finland 4Department of Epidemiology
and Biostatistics, MRC Health Protection Agency (HPA) Centre for Environment and Health, School of Public Health, Imperial College London,
London, UK 5Institute of Health Sciences, University of Oulu, PO Box 5000, FI-90014 Oulu, Finland 6Biocenter Oulu, University of Oulu,
Aapistie 5A, PO Box 5000, FI-90014 Oulu, Finland 7Unit of Primary Care, Oulu University Hospital, Kajaanintie 50, PO Box 20, FI-90220 Oulu,
90029 OYS, Finland 8Institute of Reproductive and Developmental Biology, Imperial College London, London, UK 9Department of Obstetrics
and Gynaecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland 10Department of Human Metabolism,
University of Shefﬁeld, Jessop Wing, Shefﬁeld, UK
*Correspondence address. Tel: +358-83154109; Fax: +358-83154130; E-mail: lmp@cc.oulu.ﬁ
Submitted on February 3, 2014; resubmitted on June 17, 2014; accepted on June 26, 2014
studyquestions: Can serum anti-Mu¨llerian hormone (AMH) levels measured in female adolescents predict polycystic ovary syndrome
(PCOS)-associated features in adolescence and early adulthood?
summary answer: AMH levels associated well with PCOS-associated features (such as testosterone levels and oligoamenorrhoea) in
adolescence, but was not an ideal marker to predict PCOS-associated features in early adulthood.
what is knownalready: Several studies have reported that there is a strong correlationbetween antral follicle count and serumAMH
levels and that women with PCOS/PCO have signiﬁcantly higher serum AMH levels than women with normal ovaries. Other studies have
reported an association between AMH serum levels and hyperandrogenism in adolescence, but none has prospectively assessed AMH as a
risk predictor for developing features of PCOS during adulthood.
study design, size, duration: A subset of 400 girls was selected from the prospective population-based Northern Finland Birth
Cohort 1986 (n ¼ 4567 at age 16 and n ¼ 4503 at age 26). The population has been followed from 1986 to the present.
participants/material, setting, methods: Atage16, 400 girls (100 fromeach testosteronequartile: 50witholigo-oramen-
orrhoea and50with anormalmenstrual cycle)were selectedat randomfromthe cohort forAMHmeasurement.Metabolic parameterswerealso
assessed at age 16 in all participants. Postal questionnaires enquired about oligo- or amenorrhoea, hirsutism, contraceptive use and reproductive
health at ages 16 and 26.
main results and role of chance: There was a signiﬁcant correlation between AMH and testosterone at age 16 (r ¼ 0.36,
P, 0.001). AMH levels at age 16 were signiﬁcantly higher among girls with oligo- or amenorrhoea compared with girls with normal menstrual
cycles (35.9 pmol/l [95% CI: 33.2;38.6] versus 27.7 pmol/l [95% CI: 25.0;30.4], P, 0.001). AMH at age 16 was higher in girls who developed
hirsutism at age 26 compared with the non-hirsute group (31.4 pmol/l [95% CI 27.1;36.5] versus 25.8 pmol/l [95% CI 23.3;28.6], P ¼ 0.036).
AMH at age 16 was also higher in women with PCOS at age 26 compared with the non-PCOS subjects (38.1 pmol/l [95% CI 29.1;48.4] versus
30.2 pmol/l [95% CI 27.9;32.4], P ¼ 0.044). The sensitivity and speciﬁcity of the AMH (cut-off 22.5 pmol/l) for predicting PCOS at age 26 was
85.7 and 37.5%, respectively. The addition of testosterone did not signiﬁcantly improve the accuracy of the test. There was no signiﬁcant correl-
ation between AMH levels and metabolic indices at age 16.
implications, reasons for caution: AMH is related to oligo- or amenorrhoea in adolescence, but it is not a good marker for
metabolic factors. The relatively low rate of participation in the questionnaire at age 26mayalso have affected the results. AMHwasmeasured in a
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subset of the whole cohort. AMHmeasurement is lacking international standardization and therefore the concentrations and cut-off points are
method dependent.
wider implications for the findings: Using a high enough cut-off value of AMH to predict which adolescents are likely to
developPCOS in adulthoodcould help tomanage the condition fromanearly agedue to a good sensitivity.However, becauseof its low speciﬁcity,
it is not an ideal diagnostic marker, and its routine use in clinical practice cannot, at present, be recommended.
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Introduction
Anti-Mu¨llerian hormone (AMH) plays a central role in sexual differenti-
ation by inducing the regression of the Mu¨llerian ducts in male fetuses.
In females, AMH is produced in the granulosa cells of the human ovary
after mid-gestation (Vigier et al., 1984; Rajpert-De Meyts et al., 1999;
Kuiri-Ha¨nninen et al., 2011). AMH is expressed in granulosa cells of
growing follicles up to the antral stage, suggesting an important role in
early ovarian folliculogenesis (Weenen et al., 2004; Stubbs et al.,
2005). AMH is able to inhibit the initiation of primordial follicle growth
(Durlinger et al., 2002) andmay also decrease the sensitivity of antral fol-
licles to follicle-stimulating hormone (FSH) (Durlinger et al., 1999, 2002;
Gruijters et al., 2003). Testosterone has been shown to lower AMH ex-
pression in the mammalian ovary in vitro (Crisosto et al., 2009). In
humans, however, the association between androgens and AMH
remains uncertain, and its exact function in follicular recruitment and
long-term effects is not well understood.
Polycystic ovary syndrome (PCOS) is the most common endocrine
disorder in women, producing symptoms of hyperandrogenism, oligo-
or amenorrhoea and polycystic ovaries (PCO) (Franks 1995; Ehrmann
2005). SerumAMH levels and theovarian antral follicle count (AFC) cor-
relate closely both in healthy subjects and in women with PCOS (Pigny
et al., 2003, 2006; Weenen et al., 2004). In PCOS, serum AMH corre-
lates positively with serum concentrations of testosterone (T) and nega-
tively with age (Piltonen et al., 2005). Furthermore, women with higher
serum levels of AMH and T have longermenstrual cycles comparedwith
thosewith lower levels (Kristensen et al., 2012). In linewith these obser-
vations, in non-hirsute girls with oligo-amenorrhoea (OA), the levels of
AMH are similar to those in the PCOS population but higher than in
girls with normal cycles (Hart et al., 2010a,b; Park et al., 2010a,b).
AMHhasbeen reported tobenot associatedwithmetabolic risks in ado-
lescence and in early adulthood (Lin et al., 2011; Anderson et al., 2013),
but contradictory results have been published in adult female popula-
tions (Nardo et al., 2009; Park et al., 2010a,b; Skalba et al., 2011).
The useof themeasurementof serumAMHserum levels as a diagnos-
tic tool for PCOS has been recently under debate (Dewailly et al., 2011;
Eilertsen et al., 2012; Iliodromiti et al., 2013). Women with PCOS have
higher concentrations of AMH, and accordingly, AMH correlates with
the AFC. Thus, AMH has been proposed to be a substitute for AFC in
the diagnosis of PCOS (Pigny et al., 2006; Dewailly et al., 2011; Eilertsen
et al., 2012). AMH has also been reported to correlatewith other symp-
toms of PCOS, such as hyperandrogenism and oligoamenorrhoea (Pigny
et al., 2003; Laven et al., 2004; Piltonen et al., 2005; Nardo et al., 2009;
Li et al., 2011; Skalba et al., 2011). There are, however, no follow-up
studies on the subject of AMH as a possible predictor of PCOS and its
typical symptoms (oligo- or amenorrhoea, hirsutism and hyperandro-
genism) in later life.
PCOS is also associated with increased metabolic risks in later life
(Legro 2002; Solomon et al., 2002; Nisenblat and Norman 2009). For
clinicians to be able to prevent adverse health events in PCOS, predicting
the syndrome early in life is important. We have recently reported that
oligo- or amenorrhoea at the time of adolescence is associated with
hyperandrogenaemia and may represent a risk factor for the develop-
ment of PCOS in adulthood. Furthermore, we have also reported an as-
sociation between obesity, hyperandrogenaemia and metabolic risks
among 16-year-old adolescent girls (Pinola et al., 2012).Wehypothesize
that AMH could be used as an early marker for reproductive and meta-
bolic future risks linked to PCOS to allowearly preventive actions such as
lifestyle changes.
The main aim of the present study was to elucidate the relationship
between serum AMH and testosterone levels, oligo- or amenorrhoea,
andmetabolic and cardiovascular markers at the age of 16, and to evalu-
ate whether AMH can be used as a marker for predicting future cycle
irregularities, hirsutism and diagnosis of PCOS.
Materials andMethods
Study Population
The studypopulationwas a subset of 400 subjects, from theNorthern Finland
Birth Cohort 1986 (NFBC-86), selected to be assayed for serum AMH.
The prospective NFBC-86, comprised 9362 mothers and their 9479
births (9432 children born alive), who had an expected date of birth
between 1 July 1985 and 30 June 1986, drawn from the northernmost part
of Finland. In 2001–2002, when the children were 16 years old, the adoles-
cents and their parents received postal questionnaires.Of the female adoles-
cents (n ¼ 4567) then living in Finland, either in theoriginal catchment areaor
elsewhere; 80.3% answered the questionnaire and 74% underwent clinical
examination (i.e. anthropometric measurements) and gave fasting blood
samples. After excluding twins and triplets, pregnant girls (n ¼ 20), oral
contraceptive users and users of other forms of hormonal contraception
and treatment (n ¼ 377), and subjects with incomplete data (n ¼ 824),
2448 singleton females remained eligible.
The selection of the study population for the measurement for serum
AMHwascompleted among the subjectswhoansweredbothquestionnaires
at ages 16 and 26. The study population was split into testosterone quartiles
and the ﬁnal group of study subjects (100 subjects from each testosterone
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quartile: 50 subjects with reported oligo- or amenorrhoea and 50 with
normal menstrual cycles) were randomly selected from each quartile using
a validated statistical method (SPSS software).
The questionnaire included a question about the regularity and length of
the menstrual cycle: ‘Is your menstrual cycle (the interval from the beginning
of onemenstrual period to thebeginningof thenextperiod) often (more than
twice a year) longer than 35 days?’. In addition, the girls answered to the fol-
lowing question: ‘If you are using oral contraceptives, how long was your
menstrual cycle during the year before you started any oral contraceptives?’.
The girls who had a menstrual cycle often (more than twice a year) longer
than 35 days at the time of the questionnaire and/or before the use of oral
contraceptiveswere considered to be suffering from oligo- or amenorrhoea.
In 2012, when the subjects were 26 years old, a newquestionnaire enquir-
ing about the menstrual cycles was posted to all the girls who participated in
the previous survey at age 16. This questionnaire included the same question
onoligo-oramenorrhoeaas at age16. Further, the incidenceof hirsutismwas
also self-assessed using a modiﬁed Ferriman andGallwey (F&G) score sheet.
The total response rate for 26-year-old questionnaire was 50.4%. The sub-
jects of the subpopulation used in the present study had answeredboth ques-
tionnaires. The diagnosis of PCOS was enquired from the questionnaire
(answer to the question: ‘Have you been diagnosed for PCOS by a phys-
ician?’). Additionally, womenwith both hirsutism and oligo- or amenorrhoea
according to the questionnaire at age 26 were considered to have PCOS
according to both the NIH and the Rotterdam criteria (Rotterdam
ESHRE/ASRM-Sponsored PCOS consensus workshop group, 2004).
The Ethics Committee of the Northern Ostrobothnia Hospital District
approved this study and informed consent was obtained from all subjects.
Assays
At age 16, serum samples were assayed for testosterone (T) using Agilent
triple quadrupole 6410 LC/MS equipment with an electrospray ionization
source operating in positive-ion mode (Agilent Technologies, Wilmington,
DE, USA). Multiple reaction monitoring was used to quantify testosterone
by using d3-testosterone. The intra-assay CVs of the method were 5.3, 1.6
and 1.2% for testosterone at 0.6, 6.6 and 27.7 nmol/l, respectively. The
inter-assay CVs were 5.3, 4.2 and 1.0% for the respective concentrations.
In an adult female population, an upper limit of 2.3 nmol/l is considered as
the upper normal limit in our laboratory.
Plasma glucose, total cholesterol, high-density lipoprotein cholesterol
(HDL-cholesterol), low-density lipoprotein cholesterol (LDL-cholesterol)
and triglycerides, fasting insulin, high sensitivity C-reactive protein (hsCRP)
and sex hormone binding globulin were all assayed as previously described
(Pinola et al., 2012). To quantify the degree of insulin sensitivity, homeostasis
model assessment (HOMA) valueswere calculated using the validated calcu-
lator available at http://www.dtu.ox.ac.uk.
Serum AMH concentration was assayed in the stored samples by AMH
Gen II enzyme linked immunosorbent assay (ELISA, Beckman Coulter,
Inc., 250 S. Kraemer Blvd. Brea, CA 92821 USA) as previously described
(Kumar et al., 2010; Wallace et al., 2011). Intra- and inter-assay coefﬁcients
of variationwere 4.6 and 8.0% at 0.05 ng/ml concentration; 1 ng/ml ofAMH
converts to 7.14 pmol/l.
Data analysis
The study population of 400 girls was constituted from four equal groups
(quartiles) according to their testosterone levels. TheAMH levelswere com-
pared between the four quartiles. In the whole study population and within
each testosterone quartile, a correlation analysis was carried out between
AMH and incidence of irregular anovulatory cycles/oligo-amenorrhea and
hirsutism based on the F&G scores obtained at age 26. Further, in the
whole population and in each testosterone quartile AMH was correlated
with metabolic and cardiovascular risk markers (waist–hip ratio, serum
fasting insulin, plasma fasting glucose, total cholesterol, HDL-cholesterol,
LDL-cholesterol, triglycerides, hsCRP and HOMA for insulin sensitivity),
adjusting for testosterone and BMI.
Statistical methods
The distribution of AMHwas skewed; therefore it was logarithmically trans-
formed to achieve normality in the analyses of hirsutism. The Chi square test
was used to compare categorical variables between the testosterone quar-
tiles. The conﬁdence intervals for proportions were calculated using CIA
computer program (Gardner andAltman 1989). The potential trends in con-
tinuous variables across the testosterone quartiles were examined using the
test for linear trend available in analysis of variance (ANOVA). In order to be
able to adjust for confounding variables, ANOVA and analysis of covariance
(ANCOVA) were adopted when comparing AMH levels between two
groups. Correlations were tested using Pearson’s correlation analysis.
Partial correlation analysis was used to control for confounding variables.
Bias-corrected and accelerated 95% conﬁdence intervals of the correlation
coefﬁcients were calculated with 1000 bootstrap resamples. We con-
structed a receiver operating characteristic (ROC) curve with AMH and tes-
tosterone at age 16 for PCOS at age 26. The cut-off value of AMH and
testosteronewere selected to identify PCOS subjects, with the best sensitiv-
ity and speciﬁcity. Analyses were performed by using SPSS 18.0 software
(SPSS, Inc., Chicago, IL, USA).
Results
The background characteristics of the study population are shown in the
Table I. At age 16, the BMI was signiﬁcantly increased towards greater
testosterone quartile (P-value for trend,0.001). Mean levels of testos-
terone in testosteronequartileswere1.05 in the ﬁrst, 1.46 in the second,
1.83 in the third and 2.49 nmol/l in the fourth quartile.
AMH and testosterone
Therewas a signiﬁcant correlation between serumAMH and T at age 16
[r ¼ 0.36, 95% conﬁdence interval (95% CI) 0.24–0.47, P, 0.001].
After dividing the study population into T quartiles, the correlation was
signiﬁcant only in the highest T quartile (r ¼ 0.33, 95% CI 0.01–0.56,
P ¼ 0.001). These results were independent of BMI, WHR and age at
menarche. AMH levels increased signiﬁcantly from the lowest towards
the highest T quartile (P-value for trend ,0.001, Fig. 1).
AMH and oligo- or amenorrhoea
At age 16, the girls who reported oligo- or amenorrhoea (n ¼ 200) had
higher AMH levels compared with those reporting normal cycles (n ¼
200) [35.9 pmol/l (95% CI: 33.2; 38.6) versus 27.7 pmol/l (95% CI:
25.0; 30.45), P, 0.001], and adjustment for BMI, WHR or T did not
change the results. Subjects with oligo- or amenorrhoea had higher
serum AMH levels in the second, third and fourth T quartiles compared
with thosewith regularmenstrual cycles (Fig. 2). SerumAMHlevels at age
16 did not differ signiﬁcantly between women with oligo- or amenor-
rhoea and women without oligo- or amenorrhoea at age 26.
However, within the highest testosterone quartile, the women with
oligo- or amenorrhoea (n ¼ 23) at age 26 had higher AMH levels at
age 16, compared with women with normal menstrual cycles (n ¼ 62)
at age 26, after adjusting for T and BMI [45.5 pmol/l (95% CI: 36.0;
55.1) versus 36.1 pmol/l (95% CI: 30.3; 41.9), P ¼ 0.04].
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AMH and hirsutism
After exclusion of oral contraceptive users (n ¼ 122), women with evi-
dence of hirsutism at age 26 (based on self-reported F&G score.7) had
signiﬁcantly higher AMH levels at age 16 compared with non-hirsute
counterparts (Table II). However, in the whole population, including
the oral contraceptive users, at age 26 the statistically signiﬁcant differ-
ence disappeared. Similarly, the difference disappeared after exclusion
of all those using any hormonal contraceptives (oral contraceptive pill,
minipill, hormone intrauterine device, subcutaneous implant or injec-
tion) at age 26.
AMH and PCOS
Women with PCOS at age 26 (n ¼ 21, 5, 3% of the population) had sig-
niﬁcantly higher AMH levels at age 16 (Table II). The sensitivity and spe-
ciﬁcity of the serum concentration of AMH was evaluated at age 16 for
PCOS at age 26 by using cut-off values according to the ROC-curve
(Fig. 3). The sensitivity for PCOS at age 26 with a cut-off value for
AMH of 22.5 pmol/l (3.15 ng/ml) was 85.7% and the speciﬁcity was
37.5%.When using a cut-off value for AMH of 42.9 pmol/l (6.01 ng/ml),
the sensitivity was 33.3% and the speciﬁcity was 80.0%. Combination
of different AMH and testosterone cut-offs did not signiﬁcantly improve
the accuracy of the test; the best combination was obtained with a
cut-off of 22.5 pmol/l for AMH and 1.7 nmol/l for T (ROC-curve ana-
lysis, Fig. 3), resulting in a sensitivity of 57.1% and a speciﬁcity of 69.9%.
An AMH cut-off of 22.5 pmol/l together with a T cut-off of 2.3 nmol/l
resulted into a sensitivity of 23.8% and a speciﬁcity of 87.6%. An AMH
cut-off of 42.9 pmol/l combined with a T cut-off of 1.7 nmol/l resulted
into a sensitivity of 23.8% and speciﬁcity of 89.5%, whereas the combin-
ationwith aTcut-off of 2.3 nmol/l resulted into a sensitivityof 4.8%anda
speciﬁcity of 95.2%.
AMH andmetabolic parameters
In thewhole study population, therewas a signiﬁcant butweak correlation
between serum AMH levels and BMI at the age of 16 (r ¼ 0.124, P ¼
0.013), but the signiﬁcance disappeared after adjusting for T. At age 16,
there was no signiﬁcant correlation between AMH levels and metabolic
indices (WHR, plasma fasting glucose, serum insulin, HOMA-S, hsCRP,
serum total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycer-
ides) after adjusting for testosterone and BMI, except weak correlations
in the lowest T quartile (WHR: r ¼ 20.282, P ¼ 0.005, fasting insulin:
r ¼ 0.290, P ¼ 0.004; HOMA-S: r ¼ 20.221, P ¼ 0.033).
Discussion
In thepresent study,weevaluated the relationshipbetweenAMHand tes-
tosterone, oligo- or amenorrhoea and metabolic and cardiovascular
markers, and investigated the value of AMH measurement at the age of
16 in predicting oligo- or amenorrhoea, hirsutism and the diagnosis of
PCOSat the ageof 26. The results showed thatAMH levels associated sig-
niﬁcantlywithT levels and oligo- or amenorrhoea andwere a good indica-
tor of oligo- or amenorrhoea in adolescence. A serum AMH levels over
22.5 pmol/l despite its low speciﬁcity and therefore poor value as a diag-
nostic marker, could be used also to identify the girls at risk for PCOS
in early adulthood, and allow early prevention by life style counselling.
...................................................................................................
.............................................................................................................................................................................................
Table I Background characteristics of the study population.
Characteristics of study
population
Whole
population
Testosterone quartile P-valuee
1st 2nd 3rd 4th
Socio-economic state
16 yearsa
(N ¼ 370)
White collar 21.9% (17.7; 26.1) 17.7% (10.7; 26.8) 22.6% (14.6; 32.4) 15.6% (8.8; 24.7) 31.9% (22.5; 42.5) 0.126
Blue collar 49.2% (44.1; 54.3) 53.1% (42.7; 63.4) 43.0 % (32.8; 53.7) 52.2% (41.4; 62.9) 48.4% (37.7; 59.1)
Worker 17.0% (13.2; 20.9) 17.7% (10.7; 26.8) 17.2% (10.2; 26.4) 18.9% (11.4; 28.5) 14.3% (7.8; 23.2)
Other 11.9% (8.6; 15.2) 11.5% (5.9; 19.6) 17.2% (10.2; 26.4) 13.3% (7.1; 22.1) 5.5% (1.8; 12.4)
Alcohol consumptionb
16 years
(N ¼ 399)
20.3% (16.4, 24.2) 20.0% (12.7; 29.2) 22.2% (14.5; 31.7) 15.0% (8.7; 23.5) 24.0% (16.0; 33.6) 0.421
Smokingc 16 years
(N ¼ 399)
13.3% (9.5, 16.6) 12.0% (6.4; 20.0) 15.0% (8.7; 23.5) 9.1% (4.2; 16.6) 17.0% (10.2; 25.8) 0.375
Age at menarched (year, N ¼ 320) 13.1 (1.1) 13.4 (1.0) 12.9 (1.0) 13.0 (1.2) 13.0 (1.0) 0.059
BMI 16 yearsd
(kg/m2, N ¼ 399)
21.0 (2.9) 20.3 (2.4) 21.0 (2.9) 21.2 (2.9) 21.7 (3.2) ,0.001
BMI 26 yearsd
(kg/m2, N ¼ 342)
24.2 (7.5) 23.7 (4.7) 24.5 (5.2) 23.5 (3.7) 25.0 (12.8) 0.455
WHR 16 yearsd
(N ¼ 398)
0.77 (0.04) 0.77 (0.04) 0.77 (0.04) 0.77 (0.05) 0.77 (0.04) 0.781
WHR 26 yearsd
(N ¼ 302)
0.84 (0.08) 0.84 (0.08) 0.85 (0.10) 0.85 (0.08) 0.83 (0.08) 0.573
BMI, body mass index; WHR, waist–hip ratio.
aSocio-economic state according to subjects (age 16) mothers, frequency reported, 95% conﬁdence interval in parentheses.
bOnce per month or more, frequency reported, 95% conﬁdence interval in parentheses.
c2–4 days per week or more, frequency reported, 95% conﬁdence interval in parentheses.
dMean of the variable reported, standard deviation in parentheses.
eP-value for linear trend of continuous variables and for difference between quartiles of category variables. One-way ANOVA for continuous variables and x2-test for category variables.
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Wepreviously showed that obesity in adolescence and in adulthood,
and also weight gain after adolescence, are associated with self-
reported PCOS symptoms in adulthood (Laitinen et al., 2003). Thus,
bothour previous andpresent results, and the results from intervention
studies treating PCOS (Moran et al., 2011; Teede et al., 2013) sug-
gest that the prevention of obesity and encouragement of physical ex-
ercise are important among girls at risk to prevent the syndrome from
developing.
Serum AMH levels at age 16 correlated signiﬁcantly with T levels in
adolescence and with self-reported hirsutism scores at age 26, which
supports recent ﬁndings showing a weak correlation with androgens
levels and F&G score (Eilertsen et al., 2012). In line with the present
observations, previous studies have shown that increased AMH levels
are associated with hyperandrogenism and/or oligo- or amenorrhoea
in adolescence (Park et al., 2010a,b) and adulthood (Laven et al., 2004;
Li et al., 2011). In our study, however, the correlation with hirsutism
was not signiﬁcant in the whole study population, probably because of
the beneﬁcial effect of the OCs on hirsutism.
The correlation between AMH and T levels was the strongest in the
highest T quartile, supporting our recent observation that serum T cor-
relates with oligo- or amenorrhoea at age 16 (Pinola et al., 2012). It is
probable that the hyperandrogenic girls more often have polycystic
ovaries and thereby higher serum AMH levels already in adolescence.
Unfortunately, we were not able to verify this ﬁnding as ultrasound
was not performed in this cohort, but previous studies have shown the
association both in healthy and in women with PCOS or with PCO
only (Pigny et al., 2003; Hart et al., 2010a,b).
Toourknowledge, this is theﬁrst longitudinal follow-upstudy investigat-
ing the possible value of AMH as a marker for the development of PCOS
later in early adulthood. Interestingly, the highest T quartile was the only
one inwhichAMHat age16was signiﬁcantly higher inwomenwhoexperi-
enced oligo- or amenorrhoea at age 26 compared with women with a
normal menstrual cycle. Based on the present and previous results
(Pignyetal., 2003;Hartetal., 2010a,b),wesuggest that thegirlswith irregu-
lar cycles and higher testosterone levels at age 16 have a higher antral fol-
licle count and AMH levels and are therefore likely to fulﬁl the criteria for
PCOS later in life. In line with this hypothesis, women with PCOS (either
diagnosed or self-reported symptoms according to the questionnaire) at
age 26 had higher serum AMH levels in adolescence compared with
healthy women and serum AMH levels over 22.5 pmol/l could identify
with a sensitivity of 85.7% the adolescent girls at risk for PCOS in early
adulthood. The speciﬁcity of the test remained weak but improved sub-
stantially when using a cut-off of 42.8 pmol/l. Similarly, the results of pre-
vious studies have indicated that AMHalonemay not be good enough as a
single screening tool forPCOS. In thepresent study, however, thecombin-
ation of AMH and T did not improve the accuracy of the test, in line with
some (Casadei et al., 2013), but not all studies (Eilertsen et al., 2012) in
which the power of AMH to diagnose PCOS increased substantially
when combined with the other diagnostic criteria of PCOS. The girls
with oligo- or amenorrhoea at age 16 and PCOS or hirsutism alone at
Figure 1 Mean anti-Mu¨llerian hormone (AMH) levels in different testosterone (T) quartiles. Standard deviations of the means are shown in the bars.
P-value ,0.001 for trend from the lowest towards the highest T quartile.
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age 26, however, had higher levels of AMH already at age 16, suggesting
that the association between elevated AMH and symptoms of PCOS in
adolescence persists also in early adulthood. Using a high enough cut-off
value could help to distinguish most of the hyperandrogenic adolescents
at risk for PCOS, but a routine use of this test in clinical practice cannot
at present be recommended.
Figure2 Mean anti-Mu¨llerian hormone (AMH) levels, in the subjectswith oligo- or amenorrhoea (grey) and in the subjectswith normalmenstrual cycles
(white), in testosterone quartiles, at age 16. Standard deviations of the means are shown in the bars. P-value for the difference between girls with oligo- or
amenorrhoea and girls with normal menstrual cycle in each T quartile.
.............................................................................................................................................................................................
Table II Anti-Mu¨llerian hormone (AMH) concentrations at age 16 in womenwith hirsutism or polycystic ovary syndrome
(PCOS) at age 26.
Mean AMH
concentration
(pmol/l)a
P-value
Hirsutism at age 26b (Ferriman & Gallwey score . 7)c Yes (n ¼ 34)
13.2 (11.8; 14.6)d
31.4 (27.1; 36.5)e 0.036
No (n ¼ 171)
4.4 (3.0; 5.9)d
25.8 (23.3; 28.6)e
PCOS at age 26f Yes (n ¼ 21) 38.2 (27.8; 48.5) 0.044
No (n ¼ 209) 30.2 (27.9; 32.5)
a95% conﬁdence interval in parentheses.
bAccording to modiﬁed Ferriman & Gallway score (.7).
c73 subjects missing from the analysis due to the non-response to some items, 122 oral contraceptive users excluded.
dMean Ferriman & Gallway score, 95% conﬁdence interval in parentheses.
eGeometric mean for AMH.
f170 subjects missing from the analysis due to the non-response to some items.
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Wedidnotﬁndanysigniﬁcant associationbetweenAMHandmetabolic
indices in thewhole study population at age 16,which is in agreementwith
a recent reportof a different Europeanpopulation (Anderson et al., 2013).
This result indicates that AMH, despite its association with testosterone
(Piltonenetal., 2005;Kristensenet al., 2012), is apoormarkerofmetabolic
risks in adolescence. In contrast, in other studies (Nardo et al., 2009;
Skalba et al., 2011), AMH associated positively with insulin, HOMA-IR
and negatively with HDL, and in one study (Skalba et al., 2011) also posi-
tively with total cholesterol and LDL. These studies, however, were per-
formed in older subjects in early adulthood or later, in an age range from
18 to 41. It may be that metabolic risks develop later in life and could
not be identiﬁed in our study performed in adolescence.
An important pitfall is that AMH assays lack an agreed international
standard and therefore the concentrations and cut-off points are
method dependent. Importantly, however, in this study all the measure-
mentsweremade simultaneously using the sameAMHassay.Other lim-
itations of this study are that we did not obtain blood samples from the
subjects at the age of 26 and that AMH was measured in a subset of the
whole cohort. Last, the diagnosis of PCOSat age26was basedon aques-
tionnaire, but we have previously demonstrated in a similar cohort at
age 31 (the Northern Finland Birth Cohort 1966) that self-reported
oligo- or amenorrhoea and hirsutism can identify most women with
the typical endocrine and metabolic proﬁle of PCOS (Taponen et al.,
2003, 2004).Moreover,womenwithboth symptoms fulﬁlled theRotter-
dam criteria for the deﬁnition of PCOS (Rotterdam ESHRE/ASRM-
Sponsored PCOS consensus workshop group, 2004).
Conclusion
Serum AMH levels associate signiﬁcantly with T levels and oligo- or amen-
orrhoeaat age16andareagood indicatorofoligo-oramenorrhoea inado-
lescence. Using a high enough cut-off value of AMH to predict which
adolescents are likely to develop PCOS in adulthood, despite its low spe-
ciﬁcity, could help to manage the condition from an early age with a good
sensitivity. However, it is not an ideal diagnostic marker and its routine use
in clinical practicecannot atpresentbe recommended. Furthermore,AMH
is not a good marker for cardiovascular risk factors in adolescence.
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